Simplified Diagnostic and Management Strategies for

the Diagnosis and Delivery of Health Care to those

with Obstructive Sleep Apnea

by

Nicholas Alexander Antic

MBBS (University of Adelaide 1993) FRACP (Royal Australasian College of Physicians 2001)

A thesis submitted for the degree of

DOCTOR OF PHILOSOPHY

School of Medicine

Flinders University of South Australia

5042

Adelaide Institute for Sleep Health

Repatriation General Hospital

South Australia

5041

March 2008

TABLE OF CONTENTS

V
VI
VII
x
XII
XIII
XIV
XVI

CHAPTER 1.0	_ 1
1.1 INTRODUCTION	1
1.1.1 OSA, prevalence and significance	2
1.1.2 Economic cost of OSA	
1.1.3 CPAP is a highly cost effective therapy for moderate-severe OSA	4
1.1.4 The demand and supply for OSA services in Australia	6
1.1.5 Epidemiology of OSA around the world.	7
1.1.6 World trends in OSA services	9
1.1.7 The historical development of clinical polysomnography	_10
1.1.8 Simplified diagnostic strategies for OSA	_11
1.1.8.1 Questionnaires	
1.1.8.2 Home studies to investigate sleep apnea	
1.1.8.3 Manual versus automated scoring of sleep studies	_18
1.1.8.4 Oximetry compared with other ambulatory methods of diagnosis	_19
1.1.9 Establishing patients with OSA on CPAP	
1.1.9.1 Split studies	_22
1.1.9.1 Split studies 1.1.9.2 Home Auto-adjusting CPAP to establish fixed therapeutic CPAP level	_24
1.1.9.3 Using a clinical algorithm to set the fixed CPAP level	_26
1.1.9.4 Using auto-adjusting CPAP instead of fixed CPAP for long-term care	_29
1.1.9.5 Nurse led models of care	_31
1.1.9.6 Medical manpower issues, exploring clinical care by specialist nurses	_33
1.1.9.7 Testing simplified models of care for OSA	_35
1.1.9.8 Summary of evidence on techniques used to simply the management of OSA	_37
1.2 AIMS OF THESIS	_38

CHAPTER 2.0	43
2.1 INTRODUCTION	43
2.2 METHODS	46
2.2.1 Patient selection	46
2.2.2 Portable oximetry	46
2.2.3 Study design	47
, , , ,	

2.2.4 Data analysis	48
2.2.5 Statistics	50
2.3 RESULTS	51
2.3.1 Study population	51
2.3.2 Agreement between Laboratory oximetry and PSG-defined respiratory events	53
2.3.3 Diagnostic usefulness of oximetry test results	55
2.3.4 Diagnosing OSA using a single oximetry dip rate cut point	58
2.3.5 Increasing diagnostic certainty by using different oximetry dip rate cut-points to "	rule
in" and "rule out" OSA	60
2.3.6 Home oximetry – technical reliability and comparison with laboratory results	62
2.4 DISCUSSION	64
2.4.1 Methodological limitations	69
2.4.2 Conclusion	70

3.2 METHODS 74 3.2.1 Participants 74 3.2.2 Interventions 75 3.2.2.1 Home oximetry 75 3.2.3 Objectives 75 3.2.4 Outcome measures 78 3.2.5 Sample size 86 3.2.6 Randomisation 80 3.2.7 Allocation concealment and blinding 80 3.2.8 Statistical analysis 81 3.3 RESULTS 82 3.3.1 Participant flow 82 3.3.2 Baseline data 82 3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4.1 Health Economic Considerations. 93	CHAPTER 3.0	_ 71
3.2.1 Participants 74 3.2.2 Interventions 75 3.2.2.1 Home oximetry 75 3.2.3 Objectives 76 3.2.4 Outcome measures 78 3.2.5 Sample size 78 3.2.6 Randomisation 80 3.2.7 Allocation concealment and blinding 80 3.2.8 Statistical analysis 81 3.3 RESULTS 82 3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.4.1 Health Economic Considerations. 92	3.1 INTRODUCTION	71
3.2.1 Participants 74 3.2.2 Interventions 75 3.2.2.1 Home oximetry 75 3.2.3 Objectives 76 3.2.4 Outcome measures 78 3.2.5 Sample size 78 3.2.6 Randomisation 80 3.2.7 Allocation concealment and blinding 80 3.2.8 Statistical analysis 81 3.3 RESULTS 82 3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.4.1 Health Economic Considerations. 92	3.2 METHODS	74
3.2.2 Interventions 75 3.2.2.1 Home oximetry 75 3.2.3 Objectives 75 3.2.4 Outcome measures 78 3.2.5 Sample size 80 3.2.6 Randomisation 80 3.2.7 Allocation concealment and blinding 80 3.2.8 Statistical analysis 81 3.3 RESULTS 82 3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.3 Loytime sleepiness (ESS and MWT) 87 3.3.3 CPAP Adherence 88 3.3.4 Nursing and physician consultations 90 3.3.5 Patient satisfaction 92 3.3.6 Neurocognitive Tests 92 3.4.1 Health Economic Considerations. 95	3.2.1 Participants	74
3.2.2.1 Home oximetry 75 3.2.3 Objectives 78 3.2.4 Outcome measures 78 3.2.5 Sample size 80 3.2.6 Randomisation 80 3.2.7 Allocation concealment and blinding 80 3.2.8 Statistical analysis 81 3.3 RESULTS 82 3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.3 Cubic Mathematical Consultations 87 3.3.3 CPAP Adherence 88 3.3.4 Nursing and physician consultations 90 3.3.5 Patient satisfaction 92 3.3.6 Neurocognitive Tests 92 3.4.1 Health Economic Considerations. 95	3.2.2 Interventions	75
3.2.3 Objectives 78 3.2.4 Outcome measures 78 3.2.5 Sample size 78 3.2.6 Randomisation 80 3.2.7 Allocation concealment and blinding 80 3.2.8 Statistical analysis 81 3.3 RESULTS 82 3.3.1 Participant flow 82 3.3.2 Baseline data 82 3.3.3 Outcomes 87 3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4.1 Health Economic Considerations. 95	3.2.2.1 Home oximetry	75
3.2.4 Outcome measures 78 3.2.5 Sample size 80 3.2.6 Randomisation 80 3.2.7 Allocation concealment and blinding 80 3.2.8 Statistical analysis 81 3.3 RESULTS 82 3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.4 Daytime sleepiness (ESS and MWT) 87 3.3.3 CPAP Adherence 88 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 92 3.4.1 Health Economic Considerations. 92		
3.2.6 Randomisation 80 3.2.7 Allocation concealment and blinding 80 3.2.8 Statistical analysis 81 3.3.1 Participant flow 82 3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 92 3.4.1 Health Economic Considerations. 95	3.2.4 Outcome measures	78
3.2.7 Allocation concealment and blinding 80 3.2.8 Statistical analysis 81 3.3 RESULTS 82 3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.3 CPAP Adherence 88 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 92 3.4.1 Health Economic Considerations. 92	3.2.5 Sample size	80
3.2.8 Statistical analysis 81 3.3 RESULTS 82 3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.3 CPAP Adherence 88 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 93 3.4.1 Health Economic Considerations. 95	3.2.6 Randomisation	80
3.2.8 Statistical analysis 81 3.3 RESULTS 82 3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.3 CPAP Adherence 88 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 93 3.4.1 Health Economic Considerations. 95	3.2.7 Allocation concealment and blinding	80
3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.3 CPAP Adherence 88 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 93 3.4.1 Health Economic Considerations. 95		
3.3.1 Participant flow 82 3.3.2 Baseline data 85 3.3.3 Outcomes 87 3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.3 CPAP Adherence 88 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4.1 Health Economic Considerations. 95	3.3 RESULTS	82
3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.3 CPAP Adherence 88 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 93 3.4.1 Health Economic Considerations. 95	3.3.1 Participant flow	82
3.3.3 Outcomes 87 3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.3 CPAP Adherence 88 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 93 3.4.1 Health Economic Considerations. 95	3.3.2 Baseline data	85
3.3.3.1 Daytime sleepiness (ESS and MWT) 87 3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.3 CPAP Adherence 88 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 93 3.4.1 Health Economic Considerations. 95	3.3.3 Outcomes	87
3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) 87 3.3.3.3 CPAP Adherence 88 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 93 3.4.1 Health Economic Considerations. 95	3.3.3.1 Daytime sleepiness (ESS and MWT)	87
3.3.3.3 CPAP Adherence 88 3.3.3.3 CPAP Adherence 90 3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 93 3.4.1 Health Economic Considerations. 95	3.3.3.2 Quality of Life (FOS-Q, SF-36 including Energy Vitality and Mental Health) _	87
3.3.3.4 Nursing and physician consultations 90 3.3.3.5 Patient satisfaction 92 3.3.3.6 Neurocognitive Tests 92 3.4 DISCUSSION 93 3.4.1 Health Economic Considerations. 95	3.3.3.3 CPAP Adherence	88
3.3.3.6 Neurocognitive Tests	3.3.3.4 Nursing and physician consultations	90
3.3.3.6 Neurocognitive Tests	3.3.3.5 Patient satisfaction	92
3.4.1 Health Economic Considerations95	3.3.3.6 Neurocognitive Tests	92
3.4.1 Health Economic Considerations95	3.4 DISCUSSION	93
	3.4.1 Health Economic Considerations.	95
	3.4.2 Methodological Limitations	

CHAPTER 4.0	99
4.1 INTRODUCTION	99
4.2 METHODS	104
4.2.1 Outcome Measures	104
4.2.2 MWT	105

4.2.3 Neurocognitive Testing	106
4.2.4 CPAP adherence	106
4.2.5 Quality of Life Measures	107
4.2.6 Statistical Methods	107
4.3 RESULTS	109
4.3.1 CPAP adherence	111
4.3.2 ESS	114
4.3.3 MWT	119
4.3.4 FOSQ	121
4.3.5 SF36	123

4.3.5 SF36	123
4.3.6 Integneuro (Neurocognitive) data	126
4.4 DISCUSSION	128

CHAPTER 5.0	137
5.1 SUMMARY AND CONCLUSIONS	137
5.1.2 CPAP Effectiveness 5.1.3 The Next Step	137 140 141

BIBLIOGRAPHY	144

LIST OF FIGURES

Figure 2.1. Bland-Altman plot Laboratory AHI vs. Laboratory >2%	
oximetry dip-rate	54
Figure 2.2. Receiver Operator Characteristic Curves for >2% laborate	ory
dip-rate where OSA is defined as AHI ≥ 15 and ≥30	
Figure 2.3. Bland-Altman plot Home dip-rate vs. Lab dip-rate	
Figure 3.1. Design of Clinical Trial	83
Figure 3.2. Study Flow Diagram	84
Figure 4.1. CPAP adherence Model A and Model B	.112
Figure 4.2. CPAP adherence (whole group)	.113
Figures 4.3. Pre-post treatment change in ESS as a function of	
compliance category	.115
Figure 4.4. Pre and post treatment ESS as a function of compliance	
category	.116
Figure 4.5. Total cumulative proportion of patients achieving normal	
ESS and FOSQ values with increasing compliance derived from	data
within each compliance category shown in Table 4.3 (above)	.118
Figure 4.6. Average MWT sleep latency following CPAP treatment as	а
function of compliance category	.120
Figure 4.7. Pre-post treatment total FOSQ scores as a function of	
compliance category	.122
Figure 4.8. SF36 vitality subscale change across different CPAP	
	.124
Figure 4.9. SF36 bodily pain subscale change across different CPAP	
	.125
Figure 4.10. Pre- and Post-CPAP treatment Executive maze total error	
(top) and reaction time (bottom) as a function of adherence cate	
	.128

LIST OF TABLES

Table 2.1. Patient anthropometric characteristics and PSG data	52
Table 2.2. Areas under the ROC curves ±SEM for oximetry using three	
different desaturation threshold values and two different OSA	
diagnostic cut points for AHI	57
Table 2.3. Ruling in and ruling out OSA using a single > 2% desaturation	on
dip rate cut-point	59
Table 2.4. Ruling in and Ruling out OSA using two different > 2%	
desaturation dip rate cut-points	61
Table 3.1. Group characteristics at baseline.	86
Table 3.2. Outcomes after 3 months	89
Table 3.3. Patient consultations, medical and nursing, and patient	
preference data	91
Table 4.1. Patient Characteristics1	10
Table 4.2. Percentage of patients with normal values pre- and post	
treatment and according to CPAP compliance	17
Table 4.3. Selected Neurocognitive parameters before and after CPAP,	1
and compared to a control group1	27

ABSTRACT

Obstructive sleep apnea (OSA) is a prevalent disease. Often resources to provide care for OSA are inadequate, leading to long patient waiting times. Simpler validated methods of care are needed.

In the first study in Chapter 2, the utility of a new high-sampling rate oximeter to diagnose OSA was explored. The home oximetry data collection was robust, with few failures and the data allowed the "rule in" or "rule out" of moderate-severe OSA with high degree of certainty. It is concluded that home oximetry could replace polysomnography (PSG) as a diagnostic test in a significant proportion of patients, thus allowing limited resources available for the care of those with OSA to be re-directed e.g. towards providing therapy.

In Chapter 3, the diagnostic information from the oximeter was used to underpin a study designed to demonstrate that a nurse-led model of care could produce health outcomes in moderate-severe OSA not inferior to physician-led care.

A randomised controlled multi-centre non-inferiority clinical trial was performed. 1,427 patients referred to 3 sleep medical centres with possible OSA were assessed. 195 patients were randomised to 2 models of care. Model A, a simplified model, involved home oximetry to diagnose moderatesevere OSA, auto-titrating constant positive airway pressure (APAP) to set a therapeutic constant positive airway pressure (CPAP), with all care supervised by an experienced nurse. Model B involved 2 laboratory PSG's, to diagnose OSA then titrate CPAP, supervised by a sleep physician. The

vii

primary endpoint was change in Epworth Sleepiness Score (ESS) measured before and after 3 months of CPAP. A range of other outcome measures were collected.

The change in ESS for nurse-led management (Model A) was not inferior to the physician-led service (Model B) since the lower limit of the two-sided 95% CI did not include -2, the margin of equivalence (difference 0.13, 95% CI -1.52 to -1.25). 11 patients in Model A and 10 in Model B were lost to follow up during the trial. There were no significant differences between Model A and Model B after 3 months of CPAP in any of the other outcome measures, including CPAP adherence at 3 months.

It is concluded that a simplified nurse-led model of care can produce noninferior results to physician-directed care in the management of moderatesevere OSA.

In Chapter 4 the efficacy of CPAP in normalising or improving subjective and objective sleepiness, quality of life and selected neurocognitive measures was explored. It was shown that only a proportion of patients (60% on ESS, 35% on FOSQ) normalised their scores after 3 months of CPAP therapy. This is important information. As new health care delivery strategies evolve as a result of the data presented in Chapter 3 and elsewhere, it will be crucially important to train new health care professionals in the complexities of OSA management, such that they are aware that the symptoms of patients presenting for OSA investigations can have multiple aetiologies, and may not always resolve by simply applying CPAP.

viii

The data presented in this thesis add to the evidence base in treatment of moderate-severe OSA and will help further evolve health care delivery for this important disease.

PUBLICATIONS ARISING FROM THIS THESIS

Nick A. Antic, Catherine Buchan, Adrian Esterman, Michael Hensley, Matthew T. Naughton, Sharn Rowland, Bernadette Williamson, Samantha Windler and R. Doug McEvoy. A randomised controlled trial of nurse led care for obstructive sleep apnea. American Journal of Respiratory and Critical Care Medicine (in review)

Publications (published Conference Proceedings) arising from this thesis

Antic N, Catcheside P, Hansen C, McEvoy RD. Utility of a new high sampling oximeter at the diagnosis of moderate to severe obstructive sleep apnea. ASA 2003 (Finalist New Investigator award).

Antic N, Catcheside P, Hansen C, McEvoy RD. Utility of a new high sampling oximeter at the diagnosis of moderate to severe obstructive sleep apnea. TSANZ 2004 Respirology (9) A1-75 2004 (Finalist Young Investigator Award).

Antic N, Catcheside P, Hansen C, McEvoy RD. Utility of a new high sampling oximeter at the diagnosis of moderate to severe obstructive sleep apnea. ATS 2004.

Antic N, Clark R, Hansen C, Hensley M, Naughton M, McEvoy RD. Assessing neurocognitive function in moderate-severe obstructive sleep apnea. ASA 2004.

Antic N, Clark R, Hansen C, Hensley M, Naughton M, McEvoy RD. Assessing neurocognitive function in moderate-severe obstructive sleep apnea. ATS 2005.

Nick Antic, Richard Clark, Michael Hensley, Matthew Naughton, Sam Windler, Sharn Rowland and R. Doug McEvoy. Assessment of Neurocognitive Function in moderate-severe OSA in a multi-centre trial. Australasian Sleep Association 2006.

Antic N, Hensley M, Naughton M, Rowland, S Windler S, McEvoy RD. A RCT to investigate a simplified diagnostic and management strategy for moderate-severe OSA. ATS 2007.

AWARDS

2003 Finalist Young Investigator Award Australasian Sleep Association.

2004 Finalist Ann Woolcock Young Investigator Award Thoracic Society of Australia and New Zealand.

2005 Nominated as Thoracic Society of Australia and New Zealand Young Investigator Representative to Japan Respiratory Society Annual Scientific Meeting.

DECLARATION

I certify that this thesis does not incorporate without acknowledgement any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material published or written by another person except where due reference is made in the text

Mich Ontic

March 31, 2008

ACKNOWLEDGMENTS

There are many people who have supported me through this thesis who I would like to thank.

Firstly the teams at Newcastle and Alfred Sleep Disorders Unit led by Michael Hensley and Matthew Naughton respectively.

Many Adelaide Institute for Sleep Health staff have supported this research. Special thanks to Catherine Hansen, Rachel McDonald, Paul Molyneux, Amanda Adams and the administrative staff. Special thanks to Sharn Rowland and Samantha Windler who were both integral to the data collection of the RCT and also highly professional and a pleasure to work with. Thanks also to our lab manager Jeremy Mercer, nothing is ever too hard for the team at AISH.

Thanks to Jana Bradley for her expert formatting and proof reading help.

Special thanks to my supervisors. Dr Peter Catcheside is as capable a man as I have ever met, and his help has been priceless. Everybody at the Adelaide Institute for Sleep Health who works with him are amazed by his skills. I am no exception. Professor Doug McEvoy is an inspiration to us all. He has been a superb mentor for me and given me so many opportunities. I have learnt a huge amount from him. I hope I can repay the faith he has in me one day.

My parents Ral and Vicki and my brother Alex have been unwavering in their support. I've been so fortunate to be given all the chances in life they've given me. My father has set such a high standard through his working life and given me a clear understanding of the standards I need to set for myself in my career.

Finally my wife Corinne who has given me so much over the years. I'm so fortunate to have met her. My children Holly and Lachlan are my pride and joy, I love them more than I could have imagined.

Nick Antic 31/03/08

GLOSSARY

- +LR positive likelihood ratio
- AASM American Academy of Sleep Medicine
- AHI Apnea-hypopnea index
- APAP autotitrating CPAP
- CPAP continuous positive airway pressure
- EDS excessive daytime sleepiness
- EEG electroencephalogram
- EMG electromyogram
- EOG electrooculogram
- ESS Epworth Sleepiness Scale
- FOSQ Functional Outcomes of Sleep Questionnaire
- -LR negative likelihood ratio
- MAP multivariate apnea index
- MAS mandibular advancement splint
- MVA Motor vehicle accident
- MWT Maintenance of Wakefulness Test
- NPV Negative predictive value
- ODI oxygen desaturation index
- OSA- Obstructive sleep apnea
- PPV positive predictive value
- PSG polysomnogram
- QALY quality adjusted life years
- SaO₂ arterial oxygen saturation
- SF-36- Short Form 36 (SF-36).